NASDAQ:NXTC - NextCure Stock Price, Forecast & News

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

NextCure Inc (NASDAQ:NXTC) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.02. The company had revenue of $1.58 million for the quarter, compared to the consensus estimate of $1.50 million. View NextCure's Earnings History.

NextCure is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for NextCure.

6 Wall Street analysts have issued 12-month price targets for NextCure's stock. Their forecasts range from $44.00 to $87.00. On average, they expect NextCure's share price to reach $66.17 in the next twelve months. This suggests a possible upside of 48.6% from the stock's current price. View Analyst Price Targets for NextCure.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NextCure.

News coverage about NXTC stock has been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. NextCure earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for NextCure.

NextCure saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 1,220,000 shares, an increase of 6.1% from the January 30th total of 1,150,000 shares. Based on an average trading volume of 454,600 shares, the days-to-cover ratio is presently 2.7 days. Approximately 7.6% of the company's shares are sold short. View NextCure's Current Options Chain.

Some companies that are related to NextCure include BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), SAGE Therapeutics (SAGE), Mirati Therapeutics (MRTX), PTC Therapeutics (PTCT), HUTCHISON CHINA/S (HCM), Zai Lab (ZLAB), Blueprint Medicines (BPMC), Agios Pharmaceuticals (AGIO) and Ultragenyx Pharmaceutical (RARE).

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include CVS Health (CVS), Amgen (AMGN), Alibaba Group (BABA), Honeywell International (HON), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Cisco Systems (CSCO), Home Depot (HD), Procter & Gamble (PG) and NVIDIA (NVDA).

(NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

NextCure's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sofinnova Investments Inc. (11.74%), Canaan Partners X LLC (9.91%), Lord Abbett & CO. LLC (6.34%), Alliancebernstein L.P. (4.67%), ArrowMark Colorado Holdings LLC (3.35%) and State Street Corp (1.83%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Institutional Ownership Trends for NextCure.

NXTC stock was sold by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC, EAM Global Investors LLC, EAM Investors LLC, UBS Group AG, J. Goldman & Co LP and Bamco Inc. NY. View Insider Buying and Selling for NextCure.

NXTC stock was bought by a variety of institutional investors in the last quarter, including Canaan Partners X LLC, Lord Abbett & CO. LLC, ArrowMark Colorado Holdings LLC, Alliancebernstein L.P., State Street Corp, Marshall Wace North America L.P., Sofinnova Investments Inc. and FMR LLC. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Insider Buying and Selling for NextCure.

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $44.52.

NextCure has a market capitalization of $1.01 billion. View Additional Information About NextCure.

The official website for NextCure is http://www.nextcure.com/.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]